348 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 135 of 135
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is…
Condition: Neurological Disorders / Brain Tumors
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Currently Recruiting
The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called "study drugs" and are not approved by the…
Condition: Neurological Disorders / Brain Tumors
Investigator: James Hinkley Garvin Jr, MD
Status: Currently Recruiting
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
This study is testing a drug called autogene cevumeran in combination with nivolumab, a cancertreatment drug known for treating bladder cancer. The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus nivolumab versus nivolumab on patients with Muscle Invasive Urothelial Carcinoma (MIUC.) In…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mikhail Doubrovin, MD
Status: Currently Recruiting
The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine). Lomustine (Gleostine) is already approved by the FDA for use in brain tumors but it is usually used alone and is not the first-line choice for…
Condition: Neurological Disorders / Brain Tumors
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) or astrocytoma following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during…
Condition: Neurological Disorders / Brain Tumors
Investigator: Brian Gill, MD
Status: Currently Recruiting
The purpose of this study is to see if the implantable device, Sonocloud 9, is effective getting chemotherapy to better reach your tumor compared to receiving standard-of-care chemotherapy Temozolomide and Lomustine and to see how safe and tolerable the device is. Sonocloud 9 works by making the blood-brain barrier (BBB) more permeable (allowing liquids or…
Condition: Neurological Disorders / Brain Tumors
Investigator: Aya Haggiagi, MD
Status: Currently Recruiting
The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with…
Condition: Neurological Disorders / Brain Tumors
Investigator: Aya Haggiagi, MD
Status: Currently Recruiting
The purpose of this study is to see if ONC201 is effective in treating participants with glioma when given following radiation therapy, how safe and tolerable ONC201 as compared to using placebo (a capsule that looks like ONC201 but does not contain any active drug), and to see how well ONC201 can improve quality of life and brain functioning in patients…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Condition: Cancer / Bladder Cancer
Investigator: Andrew Lenis, MD
Status: Closed
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube)…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
We are doing this research to find out the safety, toxicity, and efficacy of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of non-muscle-invasive urothelial carcinoma of the bladder that has recurred despite BCG use. The purpose of finding the maximum tolerable dose is important for future use of…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purposes of this clinical study are: To evaluate the safety and tolerability of up to 2 drug release periods of GemRIS for up to 7 days per drug release period To evaluate the pharmacokinetics (the study of the bodily absorption, distribution, metabolism, and excretion of the drug) of gemcitabine and a gemcitabine-related metabolite (product after…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this…
Condition: Cancer / Bladder Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to test how well the drug works, safety, and side effects of the experimental drug called BMS-986205. BMS-986205 will be added to another cancer medicine called nivolumab plus chemotherapy for participants who have bladder cancer that has grown into the muscle wall of the …
Condition: Cancer / Bladder Cancer
Investigator: Mark Stein, MD
Status: Closed
This clinical trial is for patients who have cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body who have already been treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI…
Condition: Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this study is to find out what effects, whether good or bad, that the combination of MOXR0916 plus atezolizumab has on you and your bladder cancer (locally advanced or metastatic urothelial cancer). Atezolizumab is approved in the United States for subjects with bladder cancer that…
Condition: Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is designed to obtain information on the safety and the effectiveness of an experimental drug called Vicinium when it is given to human subject(s)/participant(s) with bladder cancer that has not spread to the muscle of the bladder. Vicinium is part of an antibody connected to a protein…
Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
This research study is being done to see how an investigational drug called DKN-01 combined with standard cancer drugs (gemcitabine and cisplatin) works in people with biliary or gallbladder cancer. DKN-01 is an antibody that blocks the function of another protein in the body called dickkopf-1 (Dkk-1). Too much (over…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This is a research study for a vaccine called GEN-009. The main purpose of this study is to obtain information on the safety of GEN-009 and how it may activate the immune system to fight cancer. GEN-009 is a personalized vaccine. Each vaccine is made specifically for each person in the study. The vaccine is made after taking and testing cells from your…
Condition: Neurological Disorders / Brain Tumors
Investigator: Aya Haggiagi, MD
Status: Closed
Phase 2, Treatment A: This study is being done to see if your recurrent brain tumor may respond to a combination of radiosurgery (a type of radiation therapy) with nivolumab (a type of immunotherapy drug). A small number of patients have already received this combination previously and have tolerated the treatment relatively well. However, we would like to…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma.…
Condition: Neurological Disorders / Brain Tumors
Investigator: Gurcharanjeet Kaur, MD
Status: Closed
The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor.…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (…
Condition: Neurological Disorders / Brain Tumors
Investigator: Brian Gill, MD
Status: Closed
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
Optune is a portable, battery-operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a…
Condition: Neurological Disorders / Brain Tumors
Investigator: James Hinkley Garvin Jr, MD
Status: Closed
The purpose of this study is to find the best dose of a drug called MTX110 and a contrast agent called gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas, which is a kind of brain tumor. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to: See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue. See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer-related fatigue
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to find out if SL-701 is safe and tolerable for patients with recurrent glioblastoma multiforme (GBM). The study will also look at what effect SL-701 has on patient's brain tumor. SL-701 is a type of anti-cancer vaccine made up of parts 3 different short proteins called "peptides" which are frequently found on…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to find out whether an experimental drug, bevacizumab with temozolomide is safe when given to elderly patients with brain tumors and investigate the side effects of the drug combination and how often they occur. This study will also explore whether bevacizumab and temozolomide can be effective in shrinking tumors when given to…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
This research study is designed to determine whether the study drugs are effective in treating muscle invasive bladder cancer in patients whose cancer did not stop, or whose cancer returned after being treated with other drugs, and study what kind of side effects are caused by these study drugs. To do this, a group of patients…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test how well the study drug works in recurrent or isocitratedehydrogenase (IDH) mutant high grade gliomas. The study drug is called Nivolumab. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow your own body's immune system to work against tumor cells. Nivolumab is not…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The main purpose of this study is to improve treatment of ocular side effects that result from depatuxizumab mafodotin (Depatux-M) use in patients with glioblastoma (GBM). Most people treated with Depatux-M will experience eye side effects. When these side effects are not tolerated, Depatux-M is usually interrupted until symptoms improve and then restarted…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this clinical study is to evaluate safety of the study treatment, its effects on the immune system and on GBM. The study treatment includes several experimental therapies: INO-5401 + INO-9012 delivered by an electroporation device called CELLECTRA 2000 used for delivery of INO-5401 + INO-9012 into your muscle. You will also receive another…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to learn about the effects of the study drug, PF-06840003,and to find the best dose for treating research subjects/participants with malignant glioblastoma or anaplastic glioma. PF-068400003 is a new investigational drug. A new investigational drug is one that is currently not approved for sale in this country. PF-…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is being conducted to evaluate the performance of the AssureMDx test for the detection of bladder cancer in patients presenting with hematuria.
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
New data from the study of ABT-414 and ABBV-221 in patients with recurrent glioblastoma multiforme (GBM) have shown several examples where it seems evidence of disease progression (cancer that continues to grow and spread) was seen in MRI images, but examination of surgically removed tissue under the microscope did not agree with the MRI.
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
In this research study, we are looking for Information on how well nivolumab with or without ipilimumab works in combination with TTFields in adult patients with glioblastoma. You will receive the Nivolumab and/or Ipilimumab study treatment until you decide to stop study treatment or your study doctor decides to remove you from the study. This means that…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the bodys immune system to work against tumor cells. The effectiveness of BMS-936558…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
Two different studies have been developed to treat people with anaplastic glioma brain tumors. Onetreatment research study requires a tumor that has the 1p/19q co-deletion tumor marker; the other does not. This treatment research study requires that the subject has a certain kind of tumor, one that is missing part of both chromosomes 1 and 19. These missing…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to work against tumor cells.
Condition: Neurological Disorders / Brain Tumors
Investigator: Jeffrey Bruce, MD
Status: Closed
The purpose of this study is to determine the safety of directly injecting a tumor chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors.
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side…
A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This is a research study to test the effectiveness of Toca 511/Toca FC, an experimental drug, for treatment of recurring brain tumors compared to current standard of care. The study will enroll 370 subjects age 18-85 years who choose to undergo removal of the tumor a second time. At the time of surgery patients will be randomly assigned in a 1:1 ratio to…
Condition: Neurological Disorders / Brain Tumors
Investigator: Tony J. Wang, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation plus memantine to using the usual whole-brain radiation plus memantine. The hippocampus is a brain structure that is important for memory. The addition of the hippocampal avoidance technique to the usual whole-brain radiation plus…
Condition: Neurological Disorders / Brain Tumors
Investigator: Yazmin Odia, MD
Status: Closed
The purpose of this study is to test whether the new drug, ABT-414, given either alone or with a drug called temozolomide, which is commonly used to treat brain tumors like yours, gives a better outcome than the standard therapy and is safe. The standard therapy can be one of two different regimens, either a drug called lomustine or temozolomide.
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to see if the newly discovered vaccine drug, DSP-7888, will help your immune system to fight against cancer cells that have a protein called WT1. The study will also compare the effectiveness of treatment with DSP-7888 in combination with Bevacizumab versus Bevacizumab alone in patients with glioblastoma (GBM). Bevacizumab has…
Condition: Neurological Disorders / Brain Tumors
Investigator: Aya Haggiagi, MD
Status: Closed
This trial studies the side effects and best dose of nivolumab when given together with radiosurgery and to see how well they work with or without ipilimumab in treating participants with grade II-III meningioma that has come back. Nivolumab and ipilimumab (two different types of immunotherapy drugs), may interfere with the ability of tumor cells to grow…
Condition: Neurological Disorders / Brain Tumors
Investigator: Teri Kreisl, MD
Status: Closed
This is a research study to test the effects of VB-111 combined with Bevacizumab versus Bevacizumab alone on glioblastoma . This study will enroll 252 subjects age 18 years and older who have recurrent glioblastoma. All subjects will be randomly assigned in a 1:1 ratio to receive either VB-111 combined with Bevacizumab or Bevacizumab alone. Survival, tumor…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if Selinexor (KPT-330) has any effects against glioblastoma, a type of brain cancer. The study will be conducted at 3-5 sites in the United States and Europe and plan to enroll 30 patients with brain cancer. Patients will be screened prior to study participation. If their brain tumor is evaluated to require…
Condition: Neurological Disorders / Brain Tumors
Investigator: Angela Lignelli-Dipple, MD
Status: Closed
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a Phase 2b/3 study to compare the effectiveness of the study drug ABT-414 against a placebo. Patients will be randomized to either receive the standard-of-care therapy which consists of radiation therapy/TMZ plus adjuvant TMZ which will be followed by eiter the study drug ABT-414 or a placebo monotherapy.
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness ofan investigational drug to learn whether the study drug works in treating a specific disease.Investigational means that the drug is being studied. In this research study, we are looking to compare the effects, good and bad, of the standard of care…
Condition: Neurological Disorders / Brain Tumors
Investigator: Aya Haggiagi, MD
Status: Closed
This research study compares the effects (good and/or bad), of the study drug (ANG1005) with standard treatments currently available for leptomeningeal metastases to find out which is better. In this study, you will get either ANG1005 or standard treatment available for leptomeningeal metastases. You will not get both.
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This is a research study to test the effectiveness of ICT-107, an experimental drug, with the standard of care (SOC) for treatment of glioblastoma compared to enriched blood cells (PBMC) with the SOC. The study will enroll 400 subjects age 18 years and older with newly diagnosed glioblastoma. Following an initial SOC radiation treatment, patients will be…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The reason for this study is to find out if the experimental study drug, tesevatinib, is effective as a possible treatment for recurrent glioblastoma. Certain genetic information about your tumor will also be collected, by drawing blood, to help better understand why tesevatinib did or did not work in treating your recurrent glioblastoma. Although…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to investigate a novel treatment regimen for patients with recurrent Glioblastomas (GBM). In this phase 2 trial, the potentially synergistic action of PARP inhibition and anti-angiogenesis on DNA repair and biomarkers of angiogenesis and DNA repair will be evaluated.
Condition: Neurological Disorders / Brain Tumors
Investigator: Teri Kreisl, MD
Status: Closed
The purpose of this study is to find out what effects, good or bad, the experimental device, NovoTTF-100A has on patients with meningioma. This study is being done because currently there are no proveneffective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The NovoTTF-100A System is a portable medical device. It…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of the research study is to see if selinexor has any effects against your cancer and toevaluate the side-effects of selinexor or selinexor in combination with temozolomide (TMZ ). One specific way cancer cells continue to grow is by getting rid of certain proteins called tumor suppressor proteins that would normally cause cancer cells to die.…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to find out whether study drug bortezomib with radiation therapy and Temozolomide is safe when given to patients with brain tumors. This study will also evaluate the side effects and see whether the combination of bortezomib with radiation and Temozolomide can be effective in shrinking tumors. Bortezomib is the investigational…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the…
Condition: Cancer
Investigator: Andrea Califano, PhD
Status: Currently Recruiting
The purpose of this protocol is to describe the acquisition and analysis of tumor tissue samples, with the goal of identifying master regulator genes that may be targeted by existing FDA-approved drugs or late-stage experimental compounds, either individually or in combination. Should we be able to predict such therapeutic targets, drug screening will be…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Cancers include bladder cancer,…
Condition: Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the safety profile of IDE196 (an investigational drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as metastatic uveal melanoma, cervical cancer, lung cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer,…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-…
Condition: Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to evaluate the efficacy of the study drug, XL092 alone and/or in combination of other study drugs such as with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed-dose combination as a potential anticancer therapy to treat people with locally advanced or metastatic cancers including advanced renal cell cancer,…
Condition: Cancer
Investigator: Ojas Shah, MD
Status: Closed
The purpose of this study is to evaluate the effect and safety of MitoGel on patients with Upper TractUrothelial Carcinoma (UTUC). This research study is being done because this is a potentially beneficial new treatment for Low Grade UTUC. Mitomycin C (MMC) is FDA approved for other clinical indications and commercially available for the treatment of…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP-1664 has not been given to humans prior to this study. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer,…
Condition: Cancer
Investigator: Edmond Chan, MD
Status: Closed
The main purpose of the study is to find the optimal dose of HRO761 alone or in combination with tislelizumab or irinotecan that can be given to people with certain cancer types called MSI high or dMMR. The new drug being tested in the study, HRO761, is an oral drug that is called a targeted medicine: this means that it targets particular processes which…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this research study is to test the safety of an investigational drug, PRT3789, at different dose levels to find out what effects, good and/or bad, PRT3789 has on Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation. Mutations are changes or alterations in the DNA (genetic material) of your cells. A SMARCA4 mutation has been linked to…
Condition: Cancer
Investigator: Hua-Jay Cherng, MD
Status: Closed
This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body's own immune system to fight the tumor. The study drug has 2 parts. The first part,…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to assess how the study drugs, AMG 193 and IDE397, move throughout the body, how the study drugs work in the body, whether they are safe, and an effective treatment option for people with advanced solid tumors lacking methylthioadenosine phosphorylase (MTAP) in the DNA (genetic material). Lacking MTAP may limit the way in which…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb808, given in combination with pembrolizumab, has any effects on your cancer, to determine the best dose of XmAb808 to treat your cancer, and if it is safe and well-tolerated. XmAb808 is an investigational drug being developed for the treatment of advanced solid tumors. An…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to evaluate whether the investigational drug, BT7480, will be a safe and effective anticancer therapy. This is the first time BT7480 will be given to humans. BT7480 is designed to recognize and attach itself to both the Nectin-4 protein found on the surface of some cancer cells and CD137, a protein found on the surface of some…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to find out if a new investigational drug NDI-101150 is safe when given alone and in combination with pembrolizumab, and to look at the pharmacokinetics (PK, to measure how your body takes up, breaks down, and clears NDI-101150) and the antitumor activity (to measure how NDI-101150 works in your tumors). Investigational means…
Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer
Condition: Cancer
Investigator: Julia McGuinness, MD
Status: Closed
This first-in-human study will evaluate the recommended dose, safety, and effects (good and bad) of an experimental drug, BLU-222, either alone or in combination with therapies approved for some types of cancer, including carboplatin, ribociclib, and fulvestrant, to find out if these are safe and effective ways to treat nonresectable (unable to be removed…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to test a new drug called RMC-6291, to evaluate its safety at different doses, and to find out how the body processes it. RMC-6291 is a new experimental drug, which means that it is not approved by the US Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6291 will be tested…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
This study is being done to determine if a new investigational drug, LNS8801, is safe and helpful in patients with cancer that have not improved and where there are no additional standard treatment options. LNS8801 is an agonist of the G protein-coupled estrogen receptor (GPER), meaning that it can bind to this protein and turn on signaling inside the cell…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The study is being done to learn how safe and effective the study drug, RP-3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. Experimental means the study drug has not been approved for the…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells in combination with standard-of-care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of the study drug and if the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to assess the effects, good or bad, of atezolizumab and tiragolumab given with or without chemotherapy (in this study, chemotherapy will be a combination of either paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with carboplatin or cisplatin) on patients who are able to have surgery to…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The goal of this study is to determine at what dose the study treatment (ASP9801) is safe and tolerated in study participants with cancer who have tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body. This will be done by enrolling small groups of participants to receive different doses of the study…
Condition: Cancer
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to test the safety of different doses of BA3011 and to find out what effects, good and/or bad, that it has on advanced solid tumor cancers that have tested positive for the AXL protein. AXL is a protein found on certain types of cancer cells. This research study will choose the dose amount that should be studied in the future…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to learn how well RP-6306 (study drug) in combination with gemcitabine works to treat certain types of cancer. RP-6306 is a drug that is designed to stop certain cancer cells from growing by blocking a protein called PKMYT1. It is an investigational drug, which means that it has not been approved by any regulatory authorities,…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to find out whether delivering SBRT to the prostate, combined with the study drug atezolizumab, is a safe and effective treatment when given in combination with abiraterone, prednisone, and Lupron (the standard treatment for this disease). In addition, the researchers want to find out whether the study treatment works better…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body's immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
INCB106385 and INCMGA00012 are drugs being studied by Incyte Corporation for use in the treatment of advanced cancer. These study drugs are known as immune therapies, which are designed to help your immune system become more active and possibly fight your cancer. INCB106385 will be tested either alone (monotherapy) or in combination with INCMGA00012. The…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not "on the market" (available for you to receive a prescription for and/or to buy) in any country. The main goals of the study are to determine the safety, tolerability, and effects of IDE397 used as…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of the study is to help the Sponsor understand whether study drugs, AB308 together with zimberelimab (also called AB122) can be safely given to patients with advanced cancers. Zimberelimab (AB122) is an investigational drug that has been shown in animal studies to slow or stop the growth of some cancers by using the immune system. AB308 is an…
Condition: Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
In this study, we are evaluating a 30-minute pharmacist-led video consultation to provide education about your new oral anti-cancer drug (OACD) and help identify and manage potential drug-drug interactions alongside your oncologist. Our study aims to evaluate a one-time, 30-minute pharmacist-led video visit among patients starting OACDs. During the video…
Condition: Cancer
Investigator: Bret Taback, MD
Status: Closed
Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and the possibility that patients…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not received authorization to be…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this clinical trial is to find a safe and tolerated dose of the study treatment COM701 in combination with BMS-986207 and nivolumab for the treatment of advanced solid tumors. These drugs are being developed to fight cancer by using your immune system to fight the cancer cells (known as immunotherapies). These study drugs are also known as…
Condition: Cancer
Investigator: Melissa Accordino, MD
Status: Closed
Many patients with metastatic cancer experience frustration with the large number and complex scheduling of their medications. This study will help us find out how much pill burden exists in patients with advanced cancer, and how a smartphone app can help patients take their medications as their providers prescribe. Results of this study may help us figure…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to: test the safety of the study drug and see how your body handles it, find the highest dose of the study drug that can be given alone or in combination with embrolizumab (MK-3475) with the least risk of serious side effects. The study drug is called MK-2118. Solid tumor or lymphoma cancers include: …
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to learn about the safety and anti-cancer effectiveness of the investigational study drug called PF-07263689, as a single agent and in combination with sasanlimab, another investigational study drug that is an anti-PD 1 antibody. PF 07263689 is a weakened, live virus form of the pox-type virus (related to smallpox) and has been…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins are…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with incurable cancers such as, metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, triple negative breast cancer, colorectal cancer, head and neck cancer, castrate resistant prostate cancer and bladder cancer. The purpose of this study is find out whether an investigational (…
Study of Drug that May Reduce Risk of Blood Clot Development in Cancer Patients Who Are Able to Walk
Condition: Cancer
Investigator: David Diuguid, MD
Status: Closed
The purpose of this study is to see if rivaroxaban is useful in reducing the risk of patients developing blood clots while undergoing cancer treatment. The safety of rivaroxaban will also be studied. Cancer diagnoses include: pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal, or lymphoma.
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy. Cancers include: bladder…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, or renal cell carcinoma will be enrolled. The purpose of the study is to…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. The main purpose of the study is to determine at what dose the study drug is safe and tolerated. The study drug is called ASP8374. The study also wants to see how ASP3874 is processed in the blood. When the safe dose is…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this research is to learn about the effects of 2 new investigational drugs, PF-04518600 and PF-05082566. PF-04518600 and PF-05082566 are antibodies (a type of protein) which have been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental combination of lenzilumab (an antibody that blocks the cytokine GM-CSF) and axicabtagene ciloleucel (which is identical to the FDA-approved CAR-T cell product YESCARTA) helps in protecting patients from side effects of axicabtagene ciloleucel. While axicabtagene ciloleucel has been approved by the…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE